EP3463304A4 - Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases - Google Patents

Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases Download PDF

Info

Publication number
EP3463304A4
EP3463304A4 EP17802329.7A EP17802329A EP3463304A4 EP 3463304 A4 EP3463304 A4 EP 3463304A4 EP 17802329 A EP17802329 A EP 17802329A EP 3463304 A4 EP3463304 A4 EP 3463304A4
Authority
EP
European Patent Office
Prior art keywords
cannabidiol
compositions
hyaluronic acid
treating inflammatory
joint diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17802329.7A
Other languages
German (de)
French (fr)
Other versions
EP3463304A1 (en
Inventor
Tamir GEDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bol Pharma Ltd
Original Assignee
Bol Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bol Pharma Ltd filed Critical Bol Pharma Ltd
Publication of EP3463304A1 publication Critical patent/EP3463304A1/en
Publication of EP3463304A4 publication Critical patent/EP3463304A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
EP17802329.7A 2016-05-24 2017-05-24 Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases Withdrawn EP3463304A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662340576P 2016-05-24 2016-05-24
PCT/IL2017/050580 WO2017203529A1 (en) 2016-05-24 2017-05-24 Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases

Publications (2)

Publication Number Publication Date
EP3463304A1 EP3463304A1 (en) 2019-04-10
EP3463304A4 true EP3463304A4 (en) 2020-01-08

Family

ID=60411168

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17802329.7A Withdrawn EP3463304A4 (en) 2016-05-24 2017-05-24 Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases

Country Status (4)

Country Link
EP (1) EP3463304A4 (en)
CA (1) CA3025208A1 (en)
IL (1) IL263174A (en)
WO (1) WO2017203529A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210275556A1 (en) * 2018-07-02 2021-09-09 Companion Sciences. LLC Cannabidiol Combination Compositions
WO2020021545A1 (en) * 2018-07-25 2020-01-30 Bol Pharma Ltd. Cannabidiol and glucosamine for treating inflammatory joint diseases
WO2020024056A1 (en) * 2018-08-01 2020-02-06 Lazar Eve Compositions comprising cannabinoids and absorbable material and uses thereof
AU2019357608A1 (en) * 2018-10-10 2021-05-27 Tilray, Inc. Methods and formulations for treating chemotherapy-induced nausea and vomiting
US20210290562A1 (en) * 2018-12-11 2021-09-23 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
EP3935036A1 (en) * 2019-03-05 2022-01-12 Colleen Smith Veterinary compositions and methods of use therefor
US20200352849A1 (en) * 2019-05-07 2020-11-12 Adam M. Rotunda Topical Skin Formulations and Wound Care Products with Integrated CBD Delivery Mechanisms for Skin Rejuvenation, Wound Care and Healing, Pain and Itch Relief, and Scar Prevention and Treatment
IT201900008409A1 (en) * 2019-06-07 2020-12-07 Vivatis Pharma Gmbh Identification and selection of a vegetable starting material of chondroitin sulfate and vegetable hyaluronic acid, and transformation of this vegetable starting material to obtain ingredients for use in foods, supplements, medical devices or drugs
JP2022550797A (en) 2019-10-03 2022-12-05 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド Liposomal cannabinoids and their uses
US20220395547A1 (en) * 2019-11-08 2022-12-15 Vella Bioscience, Inc. Liposomal formulations for delivery of cannabinoids and methods of making thereof
EP4072590A4 (en) * 2019-12-13 2024-01-03 Folium Labs Inc Complexes comprising a carbohydrate polymer and an active ingredient and processes for their preparation
GB201918846D0 (en) * 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
EP3861996A1 (en) 2020-02-04 2021-08-11 I+Med S. Coop. Controlled release system of phytocannabinoids formulations soluble in aqueous media, methods and uses thereof
CN112138138B (en) * 2020-11-19 2023-05-23 乐康珍泰（天津）生物技术有限公司 Pharmaceutical composition for treating gout and preparation method thereof
WO2022232897A1 (en) * 2021-05-03 2022-11-10 Panag Pharma Inc. Topical liposome polyphenol compositions for treating and preventing various skin disorders and methods of preparation thereof
IT202200002000A1 (en) * 2022-02-04 2023-08-04 Mak Pharma S R L Liposomal oral composition of at least one active ingredient that is poorly absorbable at the intestinal level

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120478A1 (en) * 2004-06-08 2005-12-22 Gw Pharma Limited Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
WO2009018389A1 (en) * 2007-07-30 2009-02-05 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
EP2446884A1 (en) * 2010-10-29 2012-05-02 China Medical University Composition for inhibiting inflammation comprising hyaluronic acid and a hmg-coa reductase inhibitor
WO2014008469A2 (en) * 2012-07-05 2014-01-09 Taiwan Liposome Company, Ltd. Methods of treating arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20110142914A1 (en) * 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
WO2013114377A1 (en) * 2012-02-02 2013-08-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd Stable liposomes for drug delivery
JP2016537412A (en) * 2013-10-31 2016-12-01 フル スペクトラム ラボラトリーズ，エルティーディー． Terpenes and cannabinoid formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120478A1 (en) * 2004-06-08 2005-12-22 Gw Pharma Limited Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
WO2009018389A1 (en) * 2007-07-30 2009-02-05 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
EP2446884A1 (en) * 2010-10-29 2012-05-02 China Medical University Composition for inhibiting inflammation comprising hyaluronic acid and a hmg-coa reductase inhibitor
WO2014008469A2 (en) * 2012-07-05 2014-01-09 Taiwan Liposome Company, Ltd. Methods of treating arthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017203529A1 *

Also Published As

Publication number Publication date
IL263174A (en) 2018-12-31
CA3025208A1 (en) 2017-11-30
WO2017203529A1 (en) 2017-11-30
EP3463304A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
EP3463304A4 (en) Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
EP3347368A4 (en) Compounds and formulations for treating ophthalmic diseases
EP3261440A4 (en) Methods and compositions for treating genetic eye diseases
EP3389672A4 (en) Compositions and methods for treatment of liver diseases
EP3390634A4 (en) Compositions and methods for treatment of eye diseases
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
EP3096617A4 (en) Compositions and methods for treating ocular diseases
EP3390666A4 (en) Compositions and methods for treatment of kidney diseases
EP3319976A4 (en) Compositions and methods for treating lung diseases and lung injury
EP3826666A4 (en) Compositions and methods for treating nrp2-associated diseases
EP3592345A4 (en) Compositions and methods for treating inflammatory diseases
EP3716990A4 (en) Compositions and methods for neurological diseases
EP3310385A4 (en) Methods and compositions for treating fibrotic diseases
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3148575A4 (en) Methods and compositions for treating allergy and inflammatory diseases
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
EP3818081A4 (en) Compositions and methods for treating inflammasome related diseases or conditions
EP3275450A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis
EP3481958A4 (en) Methods and compositions for treatment of disorders and diseases involving rdh12
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
EP3570670A4 (en) Compositions and methods for treating lysosomal storage diseases and disorders
EP3393460A4 (en) Compositions and methods of treatment for mvid and related diseases
EP3265103A4 (en) Compositions and methods for treating ocular diseases
EP3430017A4 (en) Compositions and methods for treating parasitic diseases
EP3364965A4 (en) Methods and compositions for treating neurodegenerative diseases

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191211

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/127 20060101AFI20191205BHEP

Ipc: A61K 47/24 20060101ALI20191205BHEP

Ipc: A61P 19/02 20060101ALI20191205BHEP

Ipc: A61K 47/36 20060101ALI20191205BHEP

Ipc: A61K 31/352 20060101ALI20191205BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20211201